Ethyl gallate as a combination drug can overcome resistance in MRSA

Letters in Drug Design and Discovery

Volumn 8, Issue 1, 2011, Pages 65-68

  Soe, Win Mar ^a,b   Myint, Nyan Lin ^a   Sing, Lim Chu ^a,b   Sakharkar, Meena K ^a,b,c   Tang, Thean Hock ^d   Sakharkar, Kishore R ^a,d,e  

^a NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^b NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^c UNIVERSITY OF TSUKUBA   (Japan)

^d ADVANCED MEDICAL AND DENTAL INSTITUTE   (Malaysia)

^e OmicsVista   (Singapore)

Author keywords

Combination; Ethyl gallate; MPC; MRSA; MSW

Indexed keywords

FUSIDIC ACID; GALLIC ACID DERIVATIVE; GALLIC ACID ETHYL ESTER; TETRACYCLINE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ARTICLE; GENETIC STABILITY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MUTANT PREVENTION CONCENTRATION; MUTANT SELECTION WINDOW; NONHUMAN; PRIORITY JOURNAL;

EID: 78650887171     PISSN: 15701808     EISSN: None     Source Type: Journal    
DOI: 10.2174/157018011793663949     Document Type: Article

References (20)

1. Drlica, K. The mutant selection window and antimicrobial resistance. J. Antimicrob. Chemother., 2003, 52 (1), 11-17.
2. Ng, E. Y.; Trucksis, M.; Hooper, D. C. Quinolone resistance mutations in topoisomerase IV: Relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus. Antimicrob. Agents Chemother., 1996, 40(8), 1881-1888.
3. Pan, X. S.; Ambler, J.; Mehtar, S.; Fisher, L. M. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob. Agents Chemother., 1996, 40 (10), 2321-2326.
4. Garo, E.; Eldridge, G. R.; Goering, M. G.; Pulcini, E. D.; Hamilton, M. A.; Costerton, J. W.; James, G. A. Asiatic acid and corosolic acid enhance the susceptibility of Pseudomonas aeruginosa biofilms to tobramycin. Antimicrob. Agents Chemother., 2007, 51(5), 1813-1817.
5. Coutinho, H. D. M.; Costa, J. G. M.; Lima, E. O.; Falcão-Silva, V. S.; Siqueira Jr, J. P. Herbal therapy associated with antibiotic therapy: Potentiation of the antibiotic activity against methicillin - Resistant Staphylococcus aureus by Turnera ulmifolia L. BMC Complement. Altern. Med., 2009, 9, 13.
6. Coutinho, H. D. M.; Costa, J. G. M.; Lima, E. O.; Falcao-Silva, V. S.; Siqueira Jr, J. P. Enhancement of the antibiotic activity against a multiresistant Escherichia coli by Mentha arvensis L. and chlorpromazine. Chemotherapy, 2008, 54(4), 328-330.
7. Wagner, H.; Ulrich-Merzenich, G. Synergy research: Approaching a new generation of phytopharmaceuticals. Phytomedicine, 2009, 16(2-3), 97-110.
8. Ulrich-Merzenich, G.; Panek, D.; Zeitler, H.; Wagner, H.; Vetter, H. New perspectives for synergy research with the "omic"- technologies. Phytomedicine, 2009, 16(6-7), 495-508.
9. Hemaiswarya, S.; Kruthiventi, A. K.; Doble, M. Synergism between natural products and antibiotics against infectious diseases. Phytomedicine, 2008, 15(8), 639-652.
10. Barie, P. S. Antibiotic-resistant gram-positive cocci: Implications for surgical practice. World J. Surg., 1998, 22(2), 118-126.
11. Gould, F. K.; Brindle, R.; Chadwick, P. R.; Fraise, A. P.; Hill, S.; Nathwani, D.; Ridgway, G. L.; Spry, M. J.; Warren, R. E. on behalf of the, M. W. P. o. t. B. S. f. A. C. Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom. J. Antimicrob. Chemother., 2009, 63 (5), 849-861.
12. Soe, W.M.; Lin, R.; Lim, C.S.; Sakharkar, K.R.; Sakharkar, M.K. In vitro drug interactions of gallates with antibiotics in Staphylococcus aureus. Front Biosci., 2010, 2, 668-672.
13. Han, L. L.; McDougal, L. K.; Gorwitz, R. J.; Mayer, K. H.; Patel, J. B.; Sennott, J. M.; Fontana, J. L. High frequencies of clindamycin and tetracycline resistance in methicillin-resistant Staphylococcus aureus pulsed-field type USA300 isolates collected at a Boston ambulatory health center. J. Clin. Microbiol., 2007, 45(4), 1350-1352.
14. Whitby, M. Fusidic acid in the treatment of methicillin-resistant Staphylococcus aureus. Int. J. Antimicrob. Agents, 1999, 12(SUPPL. 2).
15. Schwalbe, R.; Steele-Moore, L.; Goodwin, A. C. Antimicrobial Susceptibility Testing Protocols. CRC Press: Boca Raton, 2007; p. 414.
16. Zhao, X.; Eisner, W.; Perl-Rosenthal, N.; Kreiswirth, B.; Drlica, K. Mutant prevention concentration of garenoxacin (BMS-284756) for ciprofloxacin-susceptible or -resistant Staphylococcus aureus. Antimicrob. Agents Chemother., 2003, 47(3), 1023-1027.
17. Wendy, J. M.; Sharon, L. K.; John, D. T.Resistance development in community-acquired strains of methicillin-resistant Staphylococcus aureus: an in vitro study. Int. J. Antimicrob. Agents., 2004, 24(6), 605-608.
18. Zhao, X.; Xu, C.; Domagala, J.; Drlica, K. DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance. Proc. Natl. Acad. Sci. U.S.A., 1997, 94, 13991-13996.
19. Sindelar, G.; Zhao, X.; Liew, A.; Dong, Y.; Lu, T.; Zhou, J.; Domagala, J.; Drlica, K. Mutant prevention concentration as a measure of fluoroquinolone potency against mycobacteria. Antimicrob. Agents Chemother., 2000, 44, 3337-3343.
20. Cairns, Benjamin J., Payne, Robert J. H. Bacteriophage therapy and the mutant selection window. Antimicrob. Agents Chemother., 2008, 52, 4344-4350.